NRSN
NASDAQ
$0.70
NeuroSense Therapeutics Ltd (NRSN)
Neurosense Therapeutics Ltd (NRSN) is a clinical-stage biotechnology firm dedicated to innovating treatments for neurodegenerative diseases, with a particular emphasis on Parkinson's disease. The company is advancing a diverse pipeline of therapeutic candidates through pivotal clinical trials, addressing critical unmet needs in neurology. With a seasoned management team and strategic partnerships, Neurosense is poised to develop groundbreaking therapies that not only enhance patient outcomes but also bolster its competitive position in the biopharmaceutical sector.
This company is also listed under the following ticker: NRSNW.
Website: https://www.neurosense-tx.comSector:
Healthcare
Industry:
Biotechnology
Buy
Target: $6.50 (+828.57%)
Market Cap
$23M
Free Cash Flow Yield
-32.81%
Beta (5Y)
0.57
Price Chart
Valuation
Market Cap$23M
P/B2.64
Profitability
EBITDA-$11M
EPS-$0.34
Financial Health
Free Cash Flow Yield-32.81%
Growth & Risk
EPS 5Y CAGR-17.43%
Beta (5Y)0.57
Sharpe Ratio-0.77